DCPH
Closed
Deciphera Pharmaceuticals Llc
25.61
+0.02 (+0.08%)
Last Update: 10 Jun 2024 23:09:00
Yesterday: 25.59
Day's Range: 0. - 0.
Send
sign up or login to leave a comment!
When Written:
15.45
Deciphera Pharmaceuticals LLC is a biopharmaceutical company that specializes in the development of kinase inhibitor drugs for the treatment of various types of cancer. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Deciphera's lead drug candidate is Ripretinib (formerly known as DCC-2618), which is being developed for the treatment of gastrointestinal stromal tumors (GIST) and other solid tumors. The drug is designed to selectively inhibit the activity of mutant kinases that drive the growth of cancer cells.
In addition to Ripretinib, Deciphera is also developing other kinase inhibitors for the treatment of cancer, including DCC-3116 for the treatment of solid tumors and DCC-3014 for the treatment of hematologic malignancies.
The company has partnerships with various pharmaceutical companies, including Zai Lab in China and Mundipharma in Europe, for the development and commercialization of its drugs.
Deciphera went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol DCPH.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Deciphera's lead drug candidate is Ripretinib (formerly known as DCC-2618), which is being developed for the treatment of gastrointestinal stromal tumors (GIST) and other solid tumors. The drug is designed to selectively inhibit the activity of mutant kinases that drive the growth of cancer cells.
In addition to Ripretinib, Deciphera is also developing other kinase inhibitors for the treatment of cancer, including DCC-3116 for the treatment of solid tumors and DCC-3014 for the treatment of hematologic malignancies.
The company has partnerships with various pharmaceutical companies, including Zai Lab in China and Mundipharma in Europe, for the development and commercialization of its drugs.
Deciphera went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol DCPH.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








